Showing 7461-7470 of 23127 results for "".
A New Year and New Beginnings
https://reachmd.com/series/the-practical-dermatology-podcast/a-new-year-and-new-beginnings/32417/The Practical Dermatology Podcast relaunches with the latest news to start 2025 and a conversation between Chief Medical Editor Neal Bhatia, MD, FAAD, and new Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD. Dr. Bhatia and Dr. Swanson discuss the new wave of atopic dermatitis therapeuticBalneotherapy Continued: A Future in US Dermatology?
https://reachmd.com/programs/practical-dermatology-type-ii-inflammation-journal-club/balneotherapy-continued-a-future-in-us-dermatology/54116/Practical Dermatology editorial board member Peter Lio, MD, and Karan Lal, DO, MS, FAAD, continue their discussion of the International Journal of Biometeorology article “Balneotherapy using thermal mineral water baths and dermatological diseases: a systematic review,” covering the evidence supportiThe Tumor That’s Not So Tiny: Understanding the Impact of TGCT
https://reachmd.com/programs/cme/the-tumor-thats-not-so-tiny-understanding-the-impact-of-tgct/39305/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
https://reachmd.com/programs/cme/emerging-evidence-in-focus-interpreting-data-on-next-generation-csf1r-tkis/48908/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Gaps in Shingles Vaccination: What Clinicians Need to Know
https://reachmd.com/programs/vaccination/gaps-shingles-vaccination/54087/While shingles poses a significant but preventable threat for older and immunocompromised adults, vaccination rates remain critically low. To help address this concerning gap in care, this brief video explores how we can identify eligible patients, confidently recommend vaccination, and incorporateFinerenone for CKD in Type 1 Diabetes: Updates from FINE-ONE
https://reachmd.com/programs/heart-matters/finerenone-ckd-type-1-diabetes-fine-one/35909/Chronic kidney disease (CKD) is a serious and under-addressed complication in people with type 1 diabetes. However, after limited advancements in treatment for over three decades, the FINE-ONE trial has found positive results for the use of finerenone in this patient population. Join Dr. Janet McGilExamining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
https://reachmd.com/programs/project-oncology/examining-the-treatment-paradigm-for-paroxysmal-nocturnal-hemoglobinuria/48880/Join us as we take a closer look at the current treatment options available for paroxysmal nocturnal hemoglobinuria.Diagnosing and Treating Hemochromatosis: Expert Insights
https://reachmd.com/programs/gi-insights/diagnosing-and-treating-hemochromatosis-expert-insights/39214/Hemochromatosis, a genetic condition that causes the body to absorb too much iron from food, often goes unrecognized despite its prevalance. With unique diagnostic and management challenges, it's crucial to understand how it presents, which testing strategies are most effective, and what treatment oRecognizing Neonatal FPIES: Key Clues for Early Diagnosis and Treatment
https://reachmd.com/programs/clinicians-roundtable/recognizing-neonatal-fpies-key-clues-for-early-diagnosis-and-treatment/37132/Neonatal food protein-induced enterocolitis syndrome (N-FPIES) is an underrecognized condition often misdiagnosed as necrotizing enterocolitis, despite distinct clinical and lab features that demand a different treatment approach. In this AudioAbstract, ReachMD's Ryan Quigley explores the earClosing Meningococcal Protection Gaps: The Case for Combination Vaccines
https://reachmd.com/programs/vaccination/closing-meningococcal-protection-gaps-the-case-for-combination-vaccines/37108/Despite high uptake of the quadrivalent meningococcal ACWY vaccine among adolescents, significant protection gaps remain, particularly against serogroup B. That’s why Dr. Ruth Carrico joins us to examine key challenges in adolescent vaccine delivery and how newer pentavalent vaccines covering all fi